

Xbrane

Price-beating products for major markets

Xbrane's first product offering will be Spherotide: the first generic formulation of the prostate cancer GnRH agonist triptorelin (sales \$446m) made by Xbrane's Italian subsidiary. First sales are likely to be in Iran from 2017. Bigger sales could be generated by a biosimilar of Lucentis, Xlucane, produced at a low cost using a proprietary process. Xlucane might be marketed in the US from 2021, a year after patent expiry, and from patent expiry in Europe in 2022. Lucentis sales worldwide are about \$3.6bn.

Prostate cancer – a \$500m generic opportunity

Triptorelin, branded as [Decapeptyl](#) (total sales 2015: \$446m – Ipsen sales €334m plus Allergan and Ferring) is indicated for advanced, non-metastatic prostate cancer. It also treats Endometriosis. Triptorelin is one of a well-established class that down-regulate GnRH receptors; all brands are off patent. Most sales are of three-month depot formations; continuity of dosing is crucial. The leaders are goserelin ([Zoladex](#), AstraZeneca sales 2015: \$816m) and leuprolide ([Lupron](#) Abbvie: \$826m). Generic depot formulations been very difficult to make. Spherotide is produced in Xbrane's Italian subsidiary, acquired in September 2015. Initial sales are planned to Iran in 2017; Xbrane estimates this market as worth \$30m. It is awaiting GMP approval to ship a SEK7m order. A recent Chinese SEK70m deal should yield SEK17m cash in Q117. Clinical trials will be required for approval elsewhere. EU and US applications are planned in 2018. There is no clinical data.

Lucentis – limited competition for a share of \$3.6bn

Xlucane is a biosimilar product of Lucentis (rabinizumab, Roche/Novartis 2015 sales: \$3.6bn) to treat wet acute macular degeneration (AMD). Sales fell in 2015 due to competition with Eylea (Regeneron/Bayer 2015 sales: \$4bn). Xbrane has a patented production method that lowers its bulk material cost by 85%. The process is being scaled up and needs GMP validation. For the US and EU, Xbrane plans a 400-700 patient clinical trial that might start by late 2017. The US patent on Lucentis expires in 2020 and in 2022 in Europe. A Lucentis biosimilar was launched in India by Intas in 2015. Formycon and bioeq GmbH are in Phase III aiming for H1 2020 data. Pfenex has Phase II data on PF582 but no partner. Xbrane indicates that Iran sales are possible from H217 and in EU/US upon patent expiry.

Valuation: attractive generic markets

Xbrane's value progression will depend on revenues over 2017-18 and its ability to fund and run clinical development on Spherotide and Xlucane. These are attractive generic markets. Partnering for sales into bigger markets will be needed. Cash (30 June) was SEK57m making the EV about SEK130m at the current market value.

Consensus estimates

Year end	Revenue (SEKm)	PBT (SEKm)	EPS (SEK)	DPS (SEK)	P/E (x)	Yield (%)
12/14	0.2	0.1	0.0	0.0	N/A	N/A
12/15	0.4	(11.6)	(5.2)	0.0	N/A	N/A
12/16e	N/A	N/A	N/A	N/A	N/A	N/A
12/17e	N/A	N/A	N/A	N/A	N/A	N/A

Source: Company data

Pharma & biotech

10 November 2016

Price SEK39.9
Market cap SEK188m

Share price graph



Share details

Code XBRANE
Listing NASDAQ First North
Shares in issue (current) 4.7m

Business description

Xbrane is a Swedish developer of biosimilars using a patented, more efficient bacterial culture technology. The lead product is Xlucane, a Lucentis biosimilar. Xbrane acquired an Italian slow-release generic pharmaceutical developer in 2015. The first product, Spherotide is planned for sale from 2017 in Iran.

Bull

- Spherotide sales in Iran possible from 2017 due to the less regulated market
- Limited generic competition in GnRH agonist class offering major generic substitution potential
- Only two or three Lucentis biosimilar projects

Bear

- Neither Spherotide or Xlucane has been GMP validated and there is no clinical data
- Depot formulations of GnRH agonists have been very hard to produce
- Xlucane's estimated bulk material cost advantage has to convert into competitive prices. Avastin remains as an off-label low-cost alternative

Analysts

Dr John Savin MBA +44 (0)20 3077 3735
Juan Pedro R. Serrate +44 (0)20 3681 2534
healthcare@edisongroup.com

Xbrane is a research client of Edison Investment Research limited

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Xbrane and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2016]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.